Nonalcoholic fatty liver disease is the most common liver disease in America. If you have any of these fatty liver symptoms ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

Fatty liver disease happens when fat builds up in your liver. This can cause damage, inflammation, and other complications.

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Experts warn that fatty liver disease (FLD) is becoming an epidemic in India, driven by genetics and lifestyle. With a ...

This article explores how eating junk food raises the risk of fatty liver diseases, examines symptoms, and highlights ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

Liver diseases, both acute and chronic ... the progression from simple steatosis to more severe forms like nonalcoholic ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...